Elanco Animal Health (NYSE:ELAN) Upgraded to Outperform at William Blair

William Blair upgraded shares of Elanco Animal Health (NYSE:ELAN) from a market perform rating to an outperform rating in a research note issued to investors on Thursday morning, MarketBeat.com reports.

A number of other equities research analysts have also recently issued reports on ELAN. Piper Sandler dropped their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, March 6th. UBS Group dropped their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Morgan Stanley cut their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 26th. Stifel Nicolaus raised their price target on shares of Elanco Animal Health from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Monday, May 19th. Finally, Barclays lowered their price objective on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $15.17.

Elanco Animal Health Stock Performance

Shares of NYSE ELAN opened at $14.32 on Thursday. The company has a market capitalization of $7.11 billion, a PE ratio of 19.34, a price-to-earnings-growth ratio of 2.69 and a beta of 1.67. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.46 and a current ratio of 2.71. The company’s fifty day moving average price is $12.27 and its 200 day moving average price is $11.50. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $16.15.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.06. Elanco Animal Health had a net margin of 8.43% and a return on equity of 7.54%. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period in the prior year, the company posted $0.34 EPS. The company’s revenue for the quarter was down 1.0% on a year-over-year basis. On average, research analysts predict that Elanco Animal Health will post 0.91 earnings per share for the current year.

Institutional Trading of Elanco Animal Health

Several large investors have recently bought and sold shares of the business. Allworth Financial LP raised its holdings in shares of Elanco Animal Health by 791.7% during the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock worth $25,000 after acquiring an additional 2,090 shares during the period. CoreCap Advisors LLC acquired a new position in Elanco Animal Health in the 4th quarter valued at about $29,000. Parallel Advisors LLC grew its stake in shares of Elanco Animal Health by 92.2% in the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company’s stock valued at $41,000 after buying an additional 1,852 shares during the period. NBC Securities Inc. purchased a new stake in shares of Elanco Animal Health in the 1st quarter valued at approximately $40,000. Finally, Jones Financial Companies Lllp increased its holdings in shares of Elanco Animal Health by 95.6% during the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock worth $51,000 after buying an additional 2,059 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.